维持性血透患者鞘脂与全因及心血管死亡的关联
基于HEMO研究927例维持性血透患者,基线检测16种鞘脂,中位随访2.4年发生376例死亡。长链脂肪酸(16-18碳)鞘脂与全因及心血管死亡风险升高相关,极长链(20+碳)鞘脂与风险降低相关;未发现与非遗心血管死亡的显著关联。
要点
- 长链(16-18碳)鞘脂与血透患者全因及心血管死亡风险升高相关
- 极长链(20+碳)鞘脂与血透患者全因及心血管死亡风险降低相关
- 未发现鞘脂与非遗心血管死亡显著相关
核心结论
- 在维持性血透患者中,长链脂肪酸鞘脂与全因死亡尤其心血管死亡风险升高强相关,极长链脂肪酸鞘脂与风险降低相关。
研究设计与样本
- 基于HEMO研究(多中心析因试验)数据,在927例有储存血清的参与者中,用靶向液相色谱-串联质谱法基线检测16种鞘脂,采用Cox回归分析,控制错误发现率<5%。
主要发现
- 中位随访2.4年(IQR 1.4-4.0)期间共376例死亡。
- 16种鞘脂中9种与死亡显著相关,如神经酰胺-16:0每升高两倍aHR 2.13(95%CI 1.48-3.06),神经酰胺-22:0每升高两倍aHR 0.59(95%CI 0.44-0.79)。
- 未发现任何鞘脂与非遗心血管死亡显著相关。
临床怎么用
- 鞘脂可能作为血透患者死亡风险的新型可调控标志物,但当前仅为关联性发现,尚不能用于临床常规风险分层或干预。
局限性
- 仅基线单次测量鞘脂,无法评估动态变化;研究为观察性关联分析,不能推断因果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Sphingolipids with long fatty acids (16-18 carbons) were associated with all-cause and cardiovascular death in patients treated with hemodialysis. Sphingolipids with very-long fatty acids (20+ carbons) were associated with lower risk of all-cause and cardiovascular death in dialysis patients. BACKGROUND: Patients with kidney failure on hemodialysis are at a higher risk for death, especially cardiovascular death. Statins (which improve outcomes in general populations) do not improve outcomes in dialysis patients. Sphingolipids are mechanistically associated with cardiovascular disease and may represent novel, modifiable risk factors for death in patients with kidney failure. We aimed to examine the associations of sphingolipids with death specifically in dialysis patients. METHODS: Using data from the Hemodialysis (HEMO) Study (a multicenter factorial trial of dose and flux), we measured 16 sphingolipids (ceramides-16:0, 18:0, 20:0, 22:0, 24:0, and 24:1; hexosylceramides-16:0, 22:0, and 24:0; lactosylceramide-16:0; and sphingomyelins 14:0, 16:0, 18:0, 20:0, 22:0, and 24:0) at baseline only in 927 participants with available stored serum using targeted liquid chromatography-tandem mass spectrometry. The primary outcome was all-cause death, with physician-adjudicated cause (cardiovascular versus noncardiovascular) as a secondary outcome. We examined the associations of sphingolipids with death using Cox regressions, controlling the false discovery rate <5%. RESULTS: Among 927 participants, the mean (SD) age was 57 (14) years; median (interquartile range) dialysis vintage was 1.9 (0.8-4.1) years. Over a median (interquartile range) follow-up of 2.4 (1.4-4.0) years, there were 376 deaths. Nine of 16 sphingolipids were significantly associated with death, including ceramide-16:0 (adjusted hazard ratio [aHR] 2.13 per two-fold higher concentration, 95% confidence interval, 1.48 to 3.06), and ceramide-22:0 (aHR per two-fold higher 0.59, 95% confidence interval, 0.44 to 0.79), with similar direction of associations for sphingomyelins. Twelve of 16 sphingolipids were associated with cardiovascular death, for example, ceramide-16:0 (aHR per two-fold higher 3.43, 95% confidence interval, 2.05 to 5.74). No sphingolipid was significantly associated with noncardiovascular death. CONCLUSIONS: In a dedicated study of patients with kidney failure on hemodialysis, sphingolipids with long-chain fatty acids were strongly associated with greater risk of death, especially cardiovascular death.
引用
- Lidgard B, Hoofnagle AN, Zelnick LR, et al. Association of Sphingolipids with All-Cause and Cardiovascular Death in Patients with Kidney Failure Treated with Maintenance Hemodialysis. J Am Soc Nephrol. 2025. PMID: 41563809. doi:10.1681/ASN.0000000982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。